Press Release
news head

September 6, 2018

Nucleix announces positive results in study detecting LungCancer

read more >

Press Release
news head

July 31, 2018

Cancer Screening Company Nucleix Raises 2.5 Million Euros

read more >

Press Release
news head

July 30, 2018

Israeli cancer detection co Nucleix wins €2.5m EU grant

read more >

Press Release
news head

July 26, 2018

Cancer Diagnostics Firm Nucleix Plans European Market Expansion

read more >

Press Release
news head

July 26, 2018

European study green-lights Israeli test for recurrence of bladder cancer

read more >

Press Release
news head

July 24, 2018

Nucleix Announces Publication of Non-Invasive Bladder Cancer Recurrence Detection Study Showing Best-in-Class Performance

read more >

Article
news head

July 1, 2018

Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non–muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial

read more >

Article
news head

April 12, 2018

Bladder EpiCheck Multi-Center Study Results Were Presented During the European Association of Urology (EAU) Annual Meeting

Clinical results of multi-center study with five leading urology centers were accepted as a poster and presented during the EAU meeting in Copenhagen, Denmark. The EAU meeting is the largest urology meeting in Europe and 2nd largest in the world.

read more >

Press Release
news head

April 5, 2018

Leading European Bladder Cancer Experts: The Bladder EpiCheck Urine Test Can Reduce Invasive Procedures

read more >

Article
news head

November 20, 2017

Nucleix Exhibited Bladder EpiCheck at the Annual Meeting of the European Multidisciplinary Meeting on Urological Cancers (EMUC)

Nucleix exhibited Bladder EpiCheck, best-in-class bladder cancer monitoring test, during the European Multidisciplinary Meeting on Urological Cancers (EMUC). The EMUC meeting one of Europe’s well-attended international conferences for multidisciplinary specialists with expertise in urological malignancies. During the meeting, Nucleix met

read more >